onc Videos

Videos

Conference Coverage

Study Suggests Retifanlimab Plus Chemotherapy as New Standard of Care for Locally Recurrent or Metastatic Anal Cancer

09/16/2024

Sheela Rao, MBBS, MD, discusses results from the phase 3 POD1UM-303/InterAACT 2 study which showed encouraging efficacy with retifanlimab added to standard of care chemotherapy in patients with locally recurrent or metastatic squamous cell...

Sheela Rao, MBBS, MD, discusses...

09/16/2024

Oncology

Videos

First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer

09/16/2024

Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.

Heather McArthur, MD, discusses...

09/16/2024

Oncology

Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

09/15/2024

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...

Peter Schmid, MD, PhD, discusses...

09/15/2024

Oncology

Videos

Neoadjuvant Endocrine Therapy vs De-Escalated Chemotherapy for HR-Positive, HER2-Positive Early Breast Cancer

09/15/2024

Oleg Gluz , MD;

Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...

Oleg Gluz, MD, discusses results...

09/15/2024

Oncology

Videos

Nivolumab Plus Ipilimumab Improves Overall Survival Over Standard of Care Therapy in Advanced Non-Clear Cell Renal Cancer

09/14/2024

Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.

Lothar Bergmann, MD, discusses...

09/14/2024

Oncology

Videos

Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer

09/14/2024

Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.

Filippo Piertrantonio, MD,...

09/14/2024

Oncology

Videos

Adding Relatlimab to First-Line Nivolumab and Chemotherapy Demonstrates Clinical Benefit in Advanced Non-Small Cell Lung Cancer

09/14/2024

Nicolas Girard , MD;

Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...

Nicolas Girard, MD, PhD,...

09/14/2024

Oncology

Videos

Pirtobrutinib Therapy in the R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Treatment Landscape

09/13/2024

Inhye Ahn, MD, shares insight into non-covalent BTK inhibitor pirtobrutinib treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy.

Inhye Ahn, MD, shares insight...

09/13/2024

Oncology

Videos

Updates in Novel and Cellular Therapies for Patients With R/R Multiple Myeloma

09/12/2024

Jonathan Kaufman, MD, discusses recent updates for treating patients with relapsed/refractory multiple myeloma with new and immune cellular therapies.

Jonathan Kaufman, MD, discusses...

09/12/2024

Oncology

Videos

Incidence of Endometrial Cancer Among BRCA1/2 Mutation Carriers

09/12/2024

Steve Narod, MD, discusses the incidence of endometrial cancer among people who are BRCA mutation carriers.

Steve Narod, MD, discusses the...

09/12/2024

Oncology

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology